Medigen Biotechnology Corp. (3176.TWO)

TWD 31.7

(-0.94%)

Market Cap (In TWD)

4.41 Billion

Revenue (In TWD)

1.15 Billion

Net Income (In TWD)

-561.29 Million

Avg. Volume

265.67 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
29.5-49.15
PE
-
EPS
-
Beta Value
0.575
ISIN
TW0003176004
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Shun-Lang Chang
Employee Count
-
Website
https://www.medigen.com.tw
Ipo Date
2007-12-31
Details
Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for esophageal cancer and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei, Taiwan.